26 January, 2024
We warmly welcomed a 6-member Bhutan Food and Drug Authority team as they visited our ABHL plant for the GMP certificate renewal audit from January 24-26, 2024. We are excited to announce the audit's success, reaffirming our commitment to excellence. To mark this milestone, we captured memorable moments with the BFDA team during their visit and are grateful to the BFDA team for their meticulous evaluation and collaboration. We are delighted that collaboratively, we are paving the way for excellence in the pharmaceutical industry!
24 February, 2024
Transforming Bhutan’s Healthcare Azista Bhutan Healthcare Limited Leads the Charge Thimphu, Bhutan24 February, 2024
Team Blood Donation Drive28 December, 2024
A Plant Visit Recap - ABHL Hosts DHI Group's Menjong Sorig12th July 2022
On this auspicious day, Azista Bhutan Healthcare Limited (ABHL) delivers two more products: FX24 120 mg -Fexofenadine Hydrochloride and EZEE 500 Azithromycin 500mg, in addition to the RHICET -Levocetirizine Hydrochloride and RHICET M - Montelukast 10 mg +Levocetirizine Hydrochloride 5mg that was delivered last month. In the preceding month, Lanol 500-Paracetamol was released. Today, ABHL has five medicines in the market. Many more products are already being developed and should be available to the customers soon. ABHL's goal is to ensure that Bhutanese citizens have access to high-quality, affordable, and timely medicines.
To order or to know more details about Menthopas, reach us by filling the form. We will get back you within 1-2 business days.